

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
			Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2012-13				
Opioid-induced bowel dysfunction - Methylnaltrexone (TA277)	27/03/2013	Methylnaltrexone - unable to recommend for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care because no evidence submission was received from the manufacturer of the technology.	No	NICE are unable to recommend this medicine for this indication
Cystic fibrosis (pseudomonas lung infection) - Colistimethate sodium and Tobramycin (TA276)	27/03/2013	Colistimethate sodium and Tobramycin – recommended for inhalation as possible treatments for chronic pseudomonas lung infections in some people with Cystic Fibrosis	No	This medicine is not applicable to C&W
Stroke and systemic embolism (Prevention, nonvalvular atrial fibrillation) - Apixaban (TA275)	27/02/2013	Apixaban – as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease.	Yes	
Macular oedema (diabetic) - Ranibizumab (TA274)	27/02/2013	Ranibizumab - as a possible treatment for problems with sight due to diabetic oedema in some people.	Yes	
Hyperplasia (benign prostatic) - Tadalafil (TA273)	23/01/2013	Tadalafil – unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia because no evidence submission was received from the manufacturer of the technology.	No	NICE are unable to recommend this medicine for this indication
Urothelial Tract Carcinoma (transitional cell, advanced, metastatic) - Vinflunine (TA272)	23/01/2013	Vinflunine – not recommended for people with advanced or metastatic transitional cell cancer of the urothelial tract that has been treated previously with platinum-containing cancer drugs.	Yes	
Diabetic Macular Oedema - Fluocinolone acetonide intravitreal implant (TA271)	23/01/2013	Fluocinolone - not recommended for people with chronic diabetic macular oedema when other treatments have not worked well enough	Yes	
Leukaemia (acute myeloid) – Decitabine (TA270)	12/12/2012	Decitabine - unable to make a recommendation about the use in the NHS of decitabine for acute myeloid leukaemia because no evidence submission was received from the manufacturer of the technology.	No	NICE are unable to recommend this medicine for this indication
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - Vemurafenib (TA269)	12/12/2012	vemurafenib - a possible treatment for unresectable or metastatic melanoma with the BRAF V600 mutation	Yes	

Melanoma (stage III or IV) - Ipilimumab (TA268)	12/12/2012	ipilimumab - a possible treatment for people with previously treated advanced (unresectable or metastatic) melanoma	Yes	
Chronic Heart failure - Ivabradine (TA267)	28/11/2012	Ivabradine - a possible treatment for some people with chronic heart failure	Yes	
Cystic Fibrosis - Mannitol dry powder for inhalation (TA266)	28/11/2012	Mannitol dry powder for inhalation - a possible treatment for some adults with cystic fibrosis	No	This medicine is not applicable to C&W
Bone metastases form solid tumours - Denosumab (TA265)	24/10/2012	Denosumab - Possible treatment for preventing complications that result from cancer spreading to the bone from solid tumours, except for prostate cancer, if the person would otherwise be prescribed a bisphosphonate.	Yes	
Stroke (acute ischaemic) - Alteplase (TA264)	22/08/2012	Alteplase - a possible treatment for people who have had an acute ischaemic stroke.	Yes	
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)	22/08/2012	Bevacizumab with Capecitabine – Not recommended when other chemotherapy (inc. taxanes, anthracyclines) is not appropriate, or if taxanes or anthracyclines given in past 12mths.	No	This medicine is not applicable to C&W
Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban (TA261)	23/07/2012	Rivaroxaban – a recommended option for treating DVT, and to help prevent a pulmonary embolism or another DVT.	Yes	
Ulcerative colitis (moderate to severe, second line) - adalimumab (TA262)	26/07/2012	Adalimumab – unable to recommend NHS use. TA terminated due to lack of evidence submission.	No	NICE are unable to recommend this medicine for this indication
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)	04/07/2012	Lapatinib & trastuzumab – not recommended with an aromatase inhibitor for post-menopausal women with HER2 and hormone receptor positive metastatic breast cancer.	No	This medicine is not applicable to C&W
Migraine (chronic) - botulinum toxin type A (TA260)	26/06/2012	Botulinum toxin – a recommended option for preventing headaches in some adults with chronic migraine.	Yes	
Prostate cancer (metastatic, castration resistant) - abiraterone (following cytotoxic therapy) (TA259)	20/06/2012	Abiraterone – a recommended option for metastatic prostate cancer after testosterone reduction therapy and docetaxel.	Yes	
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) (TA258)	15/06/2012	Erlotinib – a recommended first-line option in locally advanced or metastatic non-small-cell lung cancer.	Yes	
Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)	24/05/2012	Rivaroxaban – a recommended option for atrial fibrillation patients with risk factors.	Yes	
Prostate cancer - cabazitaxel (TA255)	15/05/2012	Cabazitaxel – not recommended for patients with hormone refractory, metastatic prostate cancer who have had docetaxel.	Yes	
Hepatitis C (genotype 1) - telaprevir (TA252)	14/05/2012	Telaprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous interferon treatments.	Yes	
Hepatitis C (genotype 1) - boceprevir (TA253)	14/05/2012	Boceprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous treatment.	Yes	

Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)	27/04/2012	Fingolimod – recommended for patients not responding sufficiently to beta interferon.	Yes	
Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib (TA251)	24/04/2012	For first-line treatment of chronic phase Philadelphia-chromosome-positive CML: Imatinib – recommended as an option. Nilotinib – recommended as an option only under a patient access scheme.	Yes	
Breast cancer (advanced) - eribulin (TA250)	15/04/2012	Eribulin – not recommended if cancer progressed despite two or more chemotherapy regimens.	No	This medicine is not applicable to C&W